Knudra Diagnostics

Biotech · Acquired

Platform for anthelmintic drug discovery using genetically engineered C. elegans nematodes

Grants
$750K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantNational Science Foundation · Phase II · SBIR Phase II: A Platform for Anthelmintic Drug Discovery using Genome-modified C. elegans$750,000
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1328Prox Capital Holdings, LLC—$800K
1329Parabilis Medicines——
1330Mozart Therapeutics——
1331Knudra Diagnostics——
1332NURAVAX, INC.——
1333LEUKOSIGHT, INC.——
1334JT PHARMACEUTICALS, INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.